Skip to main content

Cidara Therapeutics, Inc.

CDTXDelisted Jan 7, 2026
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001610618

Cidara Therapeutics, Inc. was delisted on Jan 7, 2026; its insiders filed their last Form 4 on Jan 9, 2026; 255 institutions reported holding it in 13F filings for Q4 2025, worth $7.36B in total; 3 superinvestors held it, including Maverick Capital and Soros Fund Management.

Holders of 5% or more of CDTX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Cidara Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of CDTX
HolderLatest formStakeChangeFirst filedLatest filingFiling
Vanguard Group Inc13G6.38%2.01M sharesNewJan 30, 20261 filingJan 30, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

60 Schedule 13D and 13G filings on Cidara Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on CDTX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Dec 16, 2021Biotechnology Value Fund L P13G/AOld format–––SEC
Oct 14, 2021Point72 Asset Management, L.P.13GOld format–New–SEC
Aug 12, 2021Interwest Partners X LP13D/AOld format–––SEC
Mar 8, 2021Lytton Laurence W13G/AOld format–––SEC
Mar 5, 2021Lytton Laurence W13GOld format–New–SEC
Feb 16, 20215AM Ventures III, L.P.13G/AOld format–––SEC
Feb 12, 2021BB Biotech AG13G/AOld format–––SEC
Feb 12, 2021Omega Fund V, L.P.13G/AOld format–––SEC
Feb 12, 2021Stonepine Capital Management, LLC13G/AOld format–––SEC
Feb 12, 2021Biotechnology Value Fund L P13G/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Cidara Therapeutics, Inc. shares.

No Form 144 notices for Cidara Therapeutics, Inc. are on file.